- Board Chair: Michael Heffernan
Mr. Heffernan is a successful entrepreneur and biopharmaceutical leader with over 25 years of experience building and leading development-stage and commercial companies. More »
Most recently, he was CEO of Collegium Pharmaceutical, a publicly traded firm focused on treatments for chronic pain and related disorders, which he founded. Prior positions have included Founder and CEO of Onset Dermatologics, which was sold to Valeant, and Co-founder and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp, of which he subsequently served as CEO and Chairman. Mr. Heffernan previously held various sales and marketing roles at Eli Lilly. He has been an advisor to, investor in, and board member for numerous biopharma, medical device, and healthcare services companies. Mr. Heffernan earned his B.S. Degree in Pharmacy from the University of Connecticut.« Less
- Board Member: Peter Barrett, Ph.D.
Dr. Barrett is a Partner at Atlas Venture, where he has been involved in the creation of numerous novel therapeutic and drug-discovery platform companies. More »
He was instrumental in the sales of Stromedix to Biogen and Novamed to SciClone Pharmaceuticals and is currently chairman of Obsidian Therapeutics, Synlogic, and Zafgen. Prior to joining Atlas in 2002, Dr. Barrett was Co-Founder, Executive Vice President, and Chief Business Officer of Celera Genomics, which completed the first successful sequencing of the human genome. He is currently Vice Chairman of the Advisory Council and Adjunct Professor at the Barnett Institute of Chemical and Biological Analysis at Northeastern University and a member of the research council at Boston Children’s Hospital. He received his B.S. in Chemistry from Lowell Technological Institute and his Ph.D. in Analytical Chemistry from Northeastern University.« Less
- Board Member: Rajesh Devraj, Ph.D.
Dr. Devraj has 20 years of pharmaceutical industry experience in drug discovery, preclinical and early clinical development, business development, and R&D strategy. More »
He currently serves as Co-Founder and CSO of Disarm Therapeutics and as an advisor for Atlas Venture. Prior roles have included CSO of Padlock Therapeutics, President & CEO of Euclises Pharmaceuticals, Senior Vice President of Deciphera Pharmaceuticals, Senior Vice President of Jubilant Drug Discovery & Development, and various positions of increasing responsibility at Pfizer and legacy Pharmacia and Searle companies. He received his Ph.D. in Medicinal Chemistry from Duquesne University and completed his Postdoctoral Fellowship at Purdue University.« Less
- Board Member: Nihal Sinha, MB BChir
Dr. Sinha is a Principal at F-Prime Capital, where he focuses on therapeutics. More »
He has been involved in a number of Series A investments and company-formation efforts in the US and Europe, including as a member of the founding team of Orchard Therapeutics. Before joining F-Prime, he served as a strategy consultant at BCG and as an academic physician at Oxford University and UCL Hospitals. Dr. Sinha holds an MB BChir from the University of Cambridge and is a Member of the Royal College of Physicians.« Less
- President & CEO: Robert Jacks
Mr. Jacks has spent 19 years in the biopharmaceutical industry focused on product development, corporate strategy, business development, fund raising, commercial analysis, finance, and operations. More »
Most recently, Mr. Jacks was the President, CFO, and Co-Founder of Symbiomix Therapeutics, a venture-backed company that was sold to Lupin Pharmaceuticals, Inc., in 2017 after achieving NDA approval for Solosec®. Prior to Symbiomix, Mr. Jacks worked for several private biotechnology firms, including Tobira Therapeutics as Head of Corporate Development and ACT Biotech as Head of Business Development. Mr. Jacks also previously worked as an Entrepreneur-in-Residence for OrbiMed and as a Director of Business Development for Pfizer, where he led the Licensing Leadership Teams for Oncology and Infectious Diseases. Mr. Jacks received an M.B.A. from Columbia Business School, an M.S.E. in Civil Engineering from Stanford University, and a B.S.E. in Civil Engineering from Duke University.« Less